PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 22, 2026RSC Medicinal Chemistry0 citations

ZRMQ-22, a Novel DYRK1A Inhibitor, Attenuates Neuroinflammation and Cognitive Impairments in LPS-Induced Mice: A Potential Strategy for Alzheimer's Disease

MRMengyu RenHCHuanhua ChenZLZhenshu Li

Key Points

  • The aim is to evaluate the effects of ZRMQ-22, a DYRK1A inhibitor, on neuroinflammation and cognitive impairments in mice.
  • Used LPS-induced mice model of neuroinflammation
  • Administered ZRMQ-22 to evaluate its effects
  • Assessed cognitive function and neuroinflammation levels
  • ZRMQ-22 significantly reduced neuroinflammation
  • Mice treated with ZRMQ-22 showed improved cognitive performance
  • The inhibitor impacted key markers associated with Alzheimer's disease

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by irreversible cognitive decline and memory loss. Targeting the kinase DYRK1A has emerged as a promising therapeutic strategy, as it plays...

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ren et al. (2026) studied this question.

synapsesocial.com/papers/699a9d8e482488d673cd386bhttps://doi.org/10.1039/d6md00007j
Ask AI
Helpful
Bookmark
Share
View Full Paper